Biologically Active Small Molecules

A melatonin receptor MT1 and MT2 agonist and competitive antagonist of human and porcine 5-HT2Creceptors (pKi = 6.2 and 6.4, respectively) as well as human 5-HT2B receptors (pKi = 6.6).

A dual antagonist of TP and EP4 receptors inhibits TxA2-induced platelet aggregation (IC₅₀ = 0.26 &muM) and bronchial smooth muscle contraction impairs PGE2-mediated relaxation of piglet saphenous vein, suppresses serum-induced

A dual antagonist of TP and EP4 receptors inhibits TxA2-induced platelet aggregation (IC₅₀ = 0.26 &muM) and bronchial smooth muscle contraction impairs PGE2-mediated relaxation of piglet saphenous vein, suppresses serum-induced

A dual antagonist of TP and EP4 receptors inhibits TxA2-induced platelet aggregation (IC₅₀ = 0.26 &muM) and bronchial smooth muscle contraction impairs PGE2-mediated relaxation of piglet saphenous vein, suppresses serum-induced

A dual antagonist of TP and EP4 receptors inhibits TxA2-induced platelet aggregation (IC₅₀ = 0.26 &muM) and bronchial smooth muscle contraction impairs PGE2-mediated relaxation of piglet saphenous vein, suppresses serum-induced

AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors. AH 6809 blocks the PGE2-induced accumulation of cAMP in COS cells transfected with the human EP2 receptor.

AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors. AH 6809 blocks the PGE2-induced accumulation of cAMP in COS cells transfected with the human EP2 receptor.

AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors. AH 6809 blocks the PGE2-induced accumulation of cAMP in COS cells transfected with the human EP2 receptor.

AH 6809 is an EP and DP receptor antagonist with nearly equal affinity for the cloned human EP1, EP2, EP3-III, and DP1 receptors. AH 6809 blocks the PGE2-induced accumulation of cAMP in COS cells transfected with the human EP2 receptor.

A selective FFAR4 antagonist (pIC₅₀s = 7.1 versus &lt 4.6 for human FFAR4 and FFAR1 receptors, respectively) that inhibits intracellular calcium accumulation induced by either linoleic acid or an FFAR4 agonist.

A selective FFAR4 antagonist (pIC₅₀s = 7.1 versus &lt 4.6 for human FFAR4 and FFAR1 receptors, respectively) that inhibits intracellular calcium accumulation induced by either linoleic acid or an FFAR4 agonist.

A selective FFAR4 antagonist (pIC₅₀s = 7.1 versus &lt 4.6 for human FFAR4 and FFAR1 receptors, respectively) that inhibits intracellular calcium accumulation induced by either linoleic acid or an FFAR4 agonist.